Keywords: Scaffoldin; Biofuels; CipA; Climate change; Cellulosome; Cohesin; Linker; NMR spectroscopy;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: AP; action potential; APD; action potential duration; APD30; APD at 30% repolarization; APD90; APD at 90% repolarization; APD30-90; APD90-APD30; [Ca2Â +]i; intracellular Ca2Â + concentration; CiPA; Comprehensive in vitro Proarrhythmia Assay; CV; condu
Keywords: oAPDc; rate corrected action potential duration; CiPA; Comprehensive in vitro Proarrhythmia Assay; oAPD50 and oAPD90; 50% and 90% duration of the optical action potential duration; EADs; early after depolarizations; hiPS-CMs; Human Induced Pluripotent Ste
Keywords: HSAN IV; CIPA; Cervical spine mass; Immune defects; NGF-NTRK1; Neuro-immune axis;
Challenges in implementing and obtaining acceptance for J-Tpeak assessment as the clinical component of CiPA
Keywords: CiPA; clinical; ECG; human; J-Tpeak; methods; QTc;
Identification of a novel mutation of the NTRK1 gene in patients with congenital insensitivity to pain with anhidrosis (CIPA)
Keywords: ALP; alkaline phosphatase; CIPA; congenital insensitivity to pain with anhidrosis; HSAN IV; autonomic neuropathy type IV; NGF; nerve growth factor; NTRK1; brachydactyly; TrkA; tyrosine kinase receptor A; β-CTX; βcross-linked C-telopeptide of type 1 coll
Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multi-electrode array (MEA) technology: A conference report
Keywords: Safety pharmacology; Cardiotoxicity; Human-induced pluripotent stem cell-derived cardiomyocytes; Multi-electrode array technology; APD; action potential duration; APC; automated patch clamp; CiPA; Comprehensive in vitro Proarrhythmia Assay; CSRC; Cardiac
Comparison of one- and three-lead ECG to measure cardiac intervals and differentiate drug-induced multi-channel block
Keywords: Automated ECG analysis; Cardiac safety; CiPA; Electrocardiogram; HESI; Methods; Multichannel block; QT interval; QT subintervals; Spatial magnitude lead;
Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are IKr blockers with proarrhythmic effects in vitro and in vivo
Keywords: DHE; dehydroevodiamine; IKr; rapid delayed rectifier current; APD; action potential duration; EAD; early afterdepolarization; cAVB; chronic atrioventricular block; TdP; Torsade de Pointes arrhythmia; hiPSC-CM; human induced pluripotent stem cell-derived c
Impact of calcium-sensitive dyes on the beating properties and pharmacological responses of human iPS-derived cardiomyocytes using the calcium transient assay
Keywords: Human stem cell cardiomyocytes; Calcium fluorescent dye; Calcium transient; Preclinical cardiac safety; Amp; amplitude; bpm; beats per minute; BR; beat rate; CiPA; Comprehensive in Vitro Proarrhythmia Assay; CTD; calcium transient duration; DMSO; dimethyl
The immature electrophysiological phenotype of iPSC-CMs still hampers in vitro drug screening: Special focus on IK1
Keywords: iPSC-CMs; IK1; Safety pharmacology; Arrhythmia; CiPA; Cardiac electrophysiology;
CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion
Keywords: Comprehensive In-Vitro Proarrhythmia assay; CiPA; hERG; Multiple cardiac ion channels; Proarrhythmia; QTc; Torsade de pointes; AV; atrioventricular; CiPA; Comprehensive In-Vitro Proarrhythmia Assay; CSRC; Cardiac Safety Research Consortium; DG; Discussion
Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes
Keywords: Arrhythmia; EAD; CardioExcyte 96; Cardiomyocytes; CiPA; Contractility; Extracellular field potential; hiPSC; Impedance; Safety pharmacology; AXG; Cor.4U®, hiPSC-CMs, Ncardia; BrCoV; Beat rate (beat period) coefficient of variation; CDI; iCell Cardiomyocy
Recurrent and novel mutations in the NTRK1 gene lead to rare congenital insensitivity to pain with anhidrosis in two Chinese patients
Keywords: CIPA; Painless fractures; Charcot arthropathy; NTRK1; Novel mutation;
Measuring kinetics and potency of hERG block for CiPA
Keywords: aLQTS; acquired long QT syndrome; CiPA; Comprehensive in vitro Proarrhythmic Assay; hERG; human ether-a-go-go related gene; AP; action potential; ICWG; Ion Channel Working Group; ISWG; In Silico Working Group; CTWG; Clinical Translation Working Group; SPS
Targeting TRK family proteins in cancer
Keywords: AKT; protein kinase B; ALK; anaplastic lymphoma kinase; ATP; adenosine triphosphate; BBB; blood-brain barrier; BDNF; brain-derived neurotrophic factor; CIPA; congenital insensitivity to pain with anhidrosis syndrome; cMET; hepatocyte growth factor recepto
Original articleOrthopaedic manifestations of congenital indifference to pain with anhidrosis (Hereditary Sensory and Autonomic Neuropathy type IV)
Keywords: Neuropathy; Autonomic neuropathy; Orthopaedic; Charcot joint; Anhidrosis; Growth; Fracture; Dislocation; CIPA; congenital indifference to pain with anhidrosis; HSAN IV; Hereditary Sensory and Autonomic Neuropathy type IV; MRI; Magnetic Resonance Imaging;
Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity
Keywords: CiPA; Torsade de pointes; Acquired long QT; Clinical risk prediction; KV11.1; Cisapride; Bepridil; Loperamide; hERG; QT interval;
CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical infor
Keywords: CSAHi; CiPA; hiPS-CMs; FPD; TdP; QT prolongation; EAD or TA; Arrest; APD; Action potential duration; CSAHi; Consortium for Safety Assessment using Human iPS Cells; CiPA; Comprehensive in vitro Proarrhythmia Assay; EAD; Early after depolarization; FPD; Fi
An evaluation of multiple algorithms for the measurement of the heart rate corrected JTpeak interval
Keywords: Electrocardiogram; Cardiac safety; QT; Long QT syndrome; CiPA; Torsade de pointes;
An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities
Keywords: Cardiotoxicity; Impedance; Cardiomyocytes; iPSC; In vitro; Drug discovery; CiPA; comprehensive in vitro proarrhythmia assay; hIPSC-CMs; human induced pluripotent stem cell cardiomyocytes; HDAC; histone deacetylase inhibitors;
Computational approaches to understand the adverse drug effect on potassium, sodium and calcium channels for predicting TdP cardiac arrhythmias
Keywords: ANN; Artificial Neural Network; CASH; Cardiac Arrest Study Hamburg; CAST; Cardiac Arrhythmia Suppression Trial; Cav1.2; L-Type calcium channel; CiPA; Comprehensive in vitro Proarrhythmic Assay; CSRC; Cardiac Safety Research Consortium; DHPs; 4-Aryl-1,4-di
Congenital insensitivity to pain with anhidrosis: A report of two siblings with a novel mutation in (TrkA) NTRK1 gene in a Saudi family
Keywords: NTRK1; CIPA; HSAN type IV; Autosomal recessive disorder; Saudi family;
The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress
Keywords: APD; action potential duration; AERS; adverse event reporting system; CiPA; Comprehensive in Vitro Proarrhythmia Assay; EAD; early after depolarizations; ECG; electrocardiogram; HESI; Health and Environmental Sciences Institute; HT; high throughput; hSC-C
A temperature-dependent in silico model of the human ether-Ã -go-go-related (hERG) gene channel
Keywords: CiPA; hERG; Kv11.1; Markov model; Methods; Temperature;
The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study
Keywords: AP; cardiac action potential; CiPA; comprehensive in vitro proarrhythmia assay; CSRC; Cardiac Safety Research Consortium; Cmax; maximal plasma concentration; CTWG; clinical translational working group; DRest; rate-normalized Tpeak â Tend = Tpe inter
Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging
Keywords: CiPA; Comprehensive in vitro Proarrhythmia Assay; TdP; Torsades de Pointes; AP; action potential; CT; Ca2Â + transient; hiPSC; human induced pluripotent stem cell; CM; cardiomyocyte; CaViar; Ca2Â + and voltage indicator; CheRiff; channelrhodopsin variant;
Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation
Keywords: Comprehensive in vitro Proarrhythmia Assay (CiPA); Field potential data sampling and analysis; Induced pluripotent cell cardiomyocytes (hiPSC-CMs); Multi electrode array (MEA); Patch clamp technologies; Pending issues and solutions; Validation; Voltage se
Molecular Architecture and Structural Transitions of a Clostridium thermocellum Mini-Cellulosome
Keywords: SAXS, small-angle X-ray scattering; 3D, three-dimensional; EM, electron microscopy; 2D, two-dimensional; RCT, random conical tilt; PDB, Protein Data Bankcellulosome; CipA; cohesin; dockerin; cryo-EM
Abnormal neutrophil chemotactic activity in children with congenital insensitivity to pain with anhidrosis (CIPA): The role of nerve growth factor
Keywords: CIPA; Neutrophils; Chemotaxis
Expanded HSAN4 phenotype associated with two novel mutations in NTRK1
Keywords: CIPA; HSAN Type IV; NTRK1; Phenotype; Mutation;
The cellulosome of Clostridium cellulolyticum
Keywords: Cellulolytic clostridia; Cellulose degradation; Cellulosome; Bacterial metabolism; Protein engineering; CBD; cellulose-binding domain; CBM; carbohydrate-binding domain; CbpA; cellulose binding protein A; Cc; Clostridium cellulolyticum; Cel; cellulase; Cip